Market News How it works Learn FAQ
| RCT 0.132 73.46% | NU 12.36 -18.47% | EWZ 33.885 -20.44% | TGL 0.254 14.67% | SRTM 0.326 -24.24% | BBD 2.855 -29.85% | ITUB 7.6 -21.41% | AZTR 1.615 125.87% | SHFS 0.103 -22.21% | XP 15.575 -48.78% | GCDT 0.1361 -22.71% | CLRO 4.79 47.38% | SOXL 91.64 9.67% | SPCX 149.92 1.65% | NWGL 0.0829 1.10% | PBR 21.94 -16.13% | NVD 3.99 -4.77% | SGRY 23.0703 46.48% | TSLL 10.9599 12.29% | VALE 11.99 -3.31% | RBNE 0.1701 -10.47% | CRWV 57.4626 5.95% | INTC 90.785 4.40% | NVDA 216.2072 2.49% | SOXS 47.41 -9.63% | BITO 10.77 -0.55% | ABEV 2.8 -15.15% | IREN 26.5486 6.60% | JBLU 2.295 -12.57% | NOK 8.625 5.96% | XTND 2.2 24.29% | SPRC 1.5001 37.62% | GPUS 0.1782 5.51% | TQQQ 69.14 4.30% | SBS 4.765 -25.55% | INTR 4.6286 -35.62% | TSLG 5.48 12.53% | RWM 14.435 -0.79% | TSLA 395.443 6.24% | SPDN 8.475 -0.76% | SQQQ 37.975 -4.30% | AAL 12.2055 0.79% | SID 0.9269 -21.45% | GGB 4.765 -6.57% | PBR-A 19.3388 -17.81% | RENT 2.9015 26.15% | LUCD 0.5155 25.43% | CIFR 8.1475 2.61% | KORU 10.9537 3.53% | WULF 12.08 6.71%
CGCG Oncology Inc. logo

CG Oncology Inc. (CGON)

NASDAQ · Currency in USD
$62.09 ▲ +0.38 (+0.62%)
As of Oct 26, 12:32 PM ET. Market open.

Summary

Previous Close
$61.71
Open
$61.76
Day's Range
$61.24 – $62.74
52 Week Range
$35.80 – $80.97
Volume
164,451
Avg. Volume
977,023
Market Cap
$5.50B
Beta (5Y Monthly)
0.24
PE Ratio (TTM)
--
EPS (TTM)
-$2.54
Earnings Date
Nov 13, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$86.50

Profile: CG Oncology Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
142
CEO
Arthur Kuan

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC.

Earnings

Next report: Fri, Nov 13, 2026
EPS estimate -$0.83 · Revenue est. $547.68K
DateEst.Actual
Aug 6, 2026-$0.66-$0.90Miss
May 8, 2026-$0.58-$0.71Miss
Feb 27, 2026-$0.61-$0.51Beat
Nov 14, 2025-$0.56-$0.57Miss
Aug 8, 2025-$0.49-$0.54Miss
May 13, 2025-$0.39-$0.45Miss

Analyst view

Consensus price target
$86.50 ▲ +39.3%
Range $80.00 – $100.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Similar stocks

Get free alerts on CGON and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.